October 8, 2026 · Phase 3 readout
ARGX Phase 3 readout: a negative outcome, -13.7%
-13.7%argenx SE (ARGX) →
On October 8, 2026, Efgartigimod IV — argenx SE (Generalized Myasthenia Gravis) reached its Phase 3 readout. The result was a negative outcome, and the stock moved -13.7% in the window around the event. It had already run -9.4% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$928.44
1d before
$801.00
Event day
$801.00
1d after
$801.00
5d after
Pre-catalyst setup
-9.4%
30-day run-up
1993%
30-day volatility
1.0×
volume spike